SCHEMBL3073989

SCHEMBL3073989

CCOc1ccc(Oc2ccc(C=O)cc2)cc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LTA4H P09960 2/20 0.59
NQO1 P15559 1/20 0.56
ALDH1A1 P00352 4/20 0.56
SMN1; SMN2 Q16637 3/20 0.56
LMNA P02545 2/20 0.56
MAPT P10636 1/20 0.56
HPGD P15428 1/20 0.56
RELA Q04206 1/20 0.53
CYP2A6 P11509 1/20 0.52
KDM4E B2RXH2 2/20 0.52
PARP10 Q53GL7 1/20 0.50
PARP3 Q9Y6F1 1/20 0.50
PTGS2 P35354 1/20 0.49
ESR1 P03372 2/20 0.47
AHR P35869 1/20 0.47
ALDH1A3 P47895 1/20 0.47
TSHR P16473 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
PIM1 P11309 1/20 0.46
PIM2 Q9P1W9 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL342467 0.94 NQO1 (0.64) NQO1ALDH1A1SMN1; SMN2LMNAMAPT
Benzene SCHEMBL28240834 0.90 RELA (0.66) LTA4HNQO1ALDH1A1SMN1; SMN2LMNA
SCHEMBL2010183 0.88 NQO1 (0.56) NQO1ALDH1A1SMN1; SMN2LMNAMAPT
Dimethylamine SCHEMBL1858794 0.88 NQO1 (0.56) NQO1ALDH1A1SMN1; SMN2LMNAMAPT
SCHEMBL18477951 0.88 ALDH1A1 (0.66) NQO1ALDH1A1SMN1; SMN2LMNAMAPT
Diethylamine SCHEMBL6101251 0.86 ALDH1A1 (0.54) NQO1ALDH1A1SMN1; SMN2LMNAMAPT
SCHEMBL26855356 0.86 ALDH1A1 (0.64) NQO1ALDH1A1SMN1; SMN2LMNAMAPT
SCHEMBL3073505 0.85 ALDH1A1 (0.67) LTA4HALDH1A1SMN1; SMN2LMNAMAPT
SCHEMBL3074037 0.85 ALDH1A1 (0.53) NQO1ALDH1A1SMN1; SMN2LMNAMAPT
SCHEMBL27768890 0.83 ALDH1A1 (0.51) NQO1ALDH1A1SMN1; SMN2LMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12329729-B1 Method of treating cancer in a subject IMAM MOHAMMAD IBN SAUD ISLAMIC UNIVERSITY (SA) 2025-06-17 US disclosed
CN-102007095-B Method for producing optically active cyanohydrin compound SUMITOMO CHEMICAL CO.,LTD. (JP) 2014-10-08 CN disclosed
CN-102007095-A Method for producing optically active cyanohydrin compound SUMITOMO CHEMICAL CO 2011-04-06 CN disclosed
US-7790744-B2 Cyclic peptide antifungal agents and process for preparation thereof ELI LILLY AND COMPANY (US) 2010-09-07 US disclosed
US-20050181984-A1 Cyclic peptide antifungal agents and process for preparation thereof ELI LILLY AND COMPANY 2005-08-18 US disclosed
US-6916784-B2 Cyclic peptide antifungal agents and process for preparation thereof ELI LILLY AND COMPANY (US) 2005-07-12 US disclosed
US-6743777-B1 TRISPHENYL ACYL DERIVATIVES OF THE ECHINOCANDIN CLASS; CANDIDA ALBICANS; ANTIFUNGAL AND ANTIPARASITIC; CYCLIC HEXAPEPTIDES HAVING UNIQUE SIDE CHAIN ACYL GROUP ELI LILLY AND COMPANY 2004-06-01 US disclosed
US-20030220236-A1 Cyclic peptide antifungal agents and process for preparation thereof ELI LILLY AND COMPANY 2003-11-27 US disclosed
EP-0736541-B1 Cyclic hexapeptide antifungal agents LILLY CO ELI (US) 2002-11-27 EP disclosed
US-6384013-B1 HETEROCYCLIC PEPTIDE FUNGICIDES ELI LILLY AND COMPANY 2002-05-07 US disclosed
US-5965525-A FOR INHIBITING FUNGAL AND PARASITIC ACTIVITIES ELI LILLY AND COMPANY (US) 1999-10-12 US disclosed
US-5652213-A CYCLIC HEXAPEPTIDE FUNGICIDES, PARASITICIDES ELI LILLY AND COMPANY (US) 1997-07-29 US disclosed
US-5646111-A Cyclic peptide antifungal Agents ELI LILLY AND COMPANY (US) 1997-07-08 US disclosed
EP-0744405-A2 Cyclic peptide antifungal agents ELI LILLY AND COMPANY (US) 1996-11-27 EP disclosed
WO-1996031228-A1 CYCLIC PEPTIDE ANTIFUNGAL AGENTS ELI LILLY AND COMPANY (US) 1996-10-10 WO disclosed
EP-0736541-A1 Cyclic hexapeptide antifungal agents ELI LILLY AND COMPANY (US) 1996-10-09 EP disclosed
EP-0561639-A1 Cyclic peptide antifungal agents and process for preparation thereof ELI LILLY AND COMPANY (US) 1993-09-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12329729-B1 Method of treating cancer in a subject IDH3B, IDH3A, HSD17B13 LTA4H 2920/4885NQO1 325/4885ALDH1A1 445/4885
US-20030220236-A1 Cyclic peptide antifungal agents and process for preparation thereof NGLY1, HM13, PTMS LTA4H 2129/4885NQO1 4728/4885ALDH1A1 4721/4885
US-20050181984-A1 Cyclic peptide antifungal agents and process for preparation thereof NGLY1, PTMS, HM13 LTA4H 2378/4885NQO1 4730/4885ALDH1A1 4825/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.